Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bismuth-206 is a cyclotron-produced radioactive isotope of bismuth with a half-life of approximately 6.24 days. It is primarily utilized in preclinical research as a diagnostic SPECT (single-photon emission computed tomography) imaging radiotracer and surrogate to evaluate the biodistribution and renal redistribution of bismuth daughter radionuclides (such as bismuth-212 and bismuth-213) generated during targeted alpha therapy (TAT) with actinium-225 or lead-212. Because bismuth naturally accumulates in renal proximal tubule epithelial cells, leading to potential nephrotoxicity, bismuth-206 serves as an imaging tool to investigate remediation strategies, such as cold metal blockade (e.g., using iron) and metal sequestration (e.g., using chelating agents like DMSA or DMPS), to reduce renal accumulation and improve the safety profile of TAT.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bismuth-206.
Work on bismuth-206? Claim this page to correct or add information. Claim this page